Recommended Macrobid Dosing
For uncomplicated urinary tract infections in adults, prescribe nitrofurantoin monohydrate/macrocrystals (Macrobid) 100 mg twice daily for 5 days. 1
Treatment Dosing for Acute Uncomplicated Cystitis
Standard Regimen
- Dose: 100 mg orally twice daily
- Duration: 5 days for women 2
- Administration: Take with food to enhance bioavailability by approximately 40% 1
The 5-day regimen achieves clinical cure rates of 88-93% and bacterial cure rates of 86-92% 3. This duration is supported by high-quality evidence showing equivalence to trimethoprim-sulfamethoxazole 3-day therapy and superiority to single-dose fosfomycin 4.
Alternative Dosing Options
While the FDA label indicates 100 mg every 12 hours for 7 days 1, contemporary guidelines support the shorter 5-day course as equally effective with potentially better adherence 2. The macrocrystal formulation at 50-100 mg four times daily for 5 days is also acceptable 2.
Men with Uncomplicated Cystitis
- Dose: 100 mg twice daily
- Duration: 7 days 2
Men require longer treatment duration due to higher risk of prostatic involvement, though evidence specifically for nitrofurantoin in men is limited 5.
Prophylaxis Dosing for Recurrent UTI
For prevention of recurrent UTIs, prescribe 50 mg once daily at bedtime. 6
Prophylactic Regimen
- Dose: 50 mg orally once daily (preferred) or 100 mg once daily
- Timing: Bedtime administration or post-coital dosing
- Duration: Continuous prophylaxis for 6-12 months
The 50 mg daily dose is strongly preferred over 100 mg for prophylaxis based on recent cohort data showing equivalent UTI prevention (hazard ratio 1.01,95% CI 0.78-1.30) but significantly fewer adverse effects 6. The 100 mg prophylactic dose was associated with increased risk of cough (HR 1.82), dyspnea (HR 2.68), and nausea (HR 2.43) compared to 50 mg 6.
Critical Renal Dosing Considerations
Avoid nitrofurantoin when creatinine clearance is <30 mL/min 5. This threshold represents strong consensus agreement, as urinary concentrations become insufficient for therapeutic efficacy below this level 5.
- CrCl ≥30 mL/min: Standard dosing appropriate
- **CrCl <30 mL/min:** Contraindicated - select alternative agent (ciprofloxacin, fosfomycin, or TMP-SMX if CrCl >15 mL/min) 5
The older recommendation to avoid nitrofurantoin at CrCl <60 mL/min lacks consensus support and is overly restrictive 5.
Key Clinical Pearls
Advantages Supporting First-Line Use
- Narrow antimicrobial spectrum minimizes collateral damage to gut microbiome 7, 8
- Extremely low resistance rates maintained over 50+ years of use 7, 8
- High urinary concentrations with minimal systemic absorption 1, 8
- Effective against ESBL-producing organisms and VRE 7
Common Pitfalls to Avoid
- Do not use for pyelonephritis or systemic infections - inadequate tissue penetration due to low serum levels 1, 8
- Do not prescribe without food - bioavailability increases 40% with meals 1
- Do not use in late pregnancy (≥38 weeks) - risk of hemolytic anemia in newborn 2
- Monitor for pulmonary reactions - rare but serious adverse effect, particularly with chronic use 5
Drug Interactions
Antagonism occurs with quinolone antibiotics in vitro; avoid concurrent use 1. Otherwise, nitrofurantoin has minimal clinically significant drug interactions compared to alternatives like TMP-SMX (warfarin, phenytoin interactions) 5.
When to Choose Alternatives
Select fosfomycin, TMP-SMX, or pivmecillinam instead when:
- CrCl <30 mL/min
- Suspected pyelonephritis or systemic infection
- Known Proteus or Pseudomonas infection (intrinsically resistant) 1
- Patient intolerance to nitrofurantoin